Source comparison
Using CJC-1295 for Anti-Aging Research Evidence: Comparison Table
Before selecting a protocol, compare the key characteristics, dosing, and evidence base across growth hormone modulation approaches. | Approach | Mechanism | Half-Life | Dosing Frequency | IGF-1 Elevation (Mean) | Evidence Strength | Professional Assessment ||
This comparison does not assign a generated winner or score.
- Before selecting a protocol, compare the key characteristics, dosing, and evidence base across growth hormone modulation approaches.
- | Approach | Mechanism | Half-Life | Dosing Frequency | IGF-1 Elevation (Mean) | Evidence Strength | Professional Assessment ||—|—|—|—|—|—|| CJC-1295 with DAC | GHRH analogue with albumin binding | 6–8 days | 1–2× weekly | 45–65% above baseline | Phase II RCT data, sustained elevation | Best-supported option for sustained anti-aging protocol. Preserves pulsatility while maintaining elevated baseline || Modified GRF (1-29) | GHRH analogue, no DAC | ~30 minutes | 1–3× daily | Transient spikes, minimal sustained change | Observational, mechanistic inference | Mimics natural pulsatility but requires multiple daily doses. Better for acute GH stimulation than chronic elevation || Exogenous GH (rhGH) | Direct hormone replacement | 3–4 hours (subcutaneous) | Daily injection | Dose-dependent, can exceed 300% | Extensive RCT data, FDA-approved indications | Strongest evidence for body composition changes but suppresses endogenous production. Not recommended for healthy aging || Ipamorelin + CJC